US and Canadian Healthcare Systems Can Implement Smoking Cessation Programs to Address Crohn’s Disease

US and Canadian Healthcare Systems Can Implement Smoking Cessation Programs to Address Crohn’s Disease
Researchers from the Institute for Public Health, University of Calgary, Canada, recently released findings from a study in which they performed a cost-utility analysis of funding smoking cessation programs for patients with Crohn’s Disease (CD). The study entitled, “Funding a smoking cessation program for Crohn's disease: an economic evaluation” was published in the most recent edition of The American Journal of Gastroenterology. Background terminology: Quality adjusted life years (QALY): a measure used in assessing the value for money of a medical intervention by the effects it has on both the quality and the quantity of a patient’s life. It is number of years of life that would be added by the intervention. Cost-utility analysis: in healthcare it measures QALYs by the value for money gained or lost between two different interventions on health outcomes. CD is a debilitating disease caused by inflammation of the lining of a patient’s digestive tract. The inflammation often spreads deep into affected tissues. The inflammation can involve the large intestine, small intestine or both.  Studies have shown that CD patients who smoke are at a higher risk of having flare up and requiring surgical interventions to alleviate their symptoms. Therefore, smoking cessation initiatives should most likely be implemented for this population. Currently, there is very little data available as to the cost-effectiveness of implementing smoking cessation programs. This study was an effort by these researchers to close this data gap by performing a cost-utility analysis of funding smoking cessation programs for patients with CD, and the budgetary impact the programs would have on certain western healthcare systems. Study Results: The investigators compared 5 diff
Subscribe or to access all post and page content.